Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction

Transplantation

Volumn 70, Issue 1, 2000, Pages 143-148

  Smak Gregoor, Peter J H ^a   Van Gelder, Teun ^a   Van Besouw, Nicole M ^a   Van Der Mast, Barbara J ^a   Ijzermans, Jan N M ^a   Weimar, Willem ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID;

EID: 0034662213     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Myers BD, Newton L, Oyer P. The case against the indefinite use of cyclosporine. Transpl Proc 1991; 51: 118
2. Arend SM, Mallat MJ, Westendorp RJW, van der Woude FJ, van Es LA. Patient survival after renal transplantation: More than 25 years follow-up. Nephrol Dial Transplant 1997; 12: 1672
3. Kasiske BL, Guijarro C, Massy AZ, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158
4. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331
5. Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. Arch Intern Med 1990; 150: 280
6. Raine AEG, Margreiter R, Brunner FP, et al. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7(Suppl.2): 7
7. Raine AEG. Hypertension and ischemic heart disease in renal transplant recipients. Nephrol Dial Transplant 1995; 10(Suppl.1): 95
8. Penn I. Malignancy. Surg Clin North Am 1994;74
9. Morris PJ, French ME, Dunnill MS, et al. A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation 1983; 36: 273
10. Adu D, Micheal J, McMaster P. Conversion from cyclosporin to azathioprine/prednisolone. Lancet 1985; 1: 392
11. Hoitsma AJ, Wetzels JFM, van Lier HJJ, Berden JHM, Koene RAP. Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients. Lancet 1987; 1: 584
12. Hall BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318: 1499
13. van den Dorpel MA, Ghanem H, Rischen-Vos J, Man in 't Veld AJ, Jansen H, Weimar W. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 1997; 51: 1608
14. Versluis DJ, Wenting GJ, Derkx FHM, Schalekamp MADH, Jeekel J, Weimar W. Who should be converted from cyclosporin A to conventional immunosuppression in kidney transplantation and why? Transplantation 1987; 44: 387
15. Sagalowsky AI, Reisman ME, Dawidson I, Toto R, Peters PC, Helderman JH. Late conversion carries risk of irreversible rejection. Transplant Proc 1988; 20: 157
16. Hollander AAMJ, van Saase JLCM, Kootte AMM, et al. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation. Lancet 1995; 345: 610
17. Pedersen EB, Hansen HE, Kornerup HJ, Madsen S, Sorensen AWS. Long term graft survival after conversion from cyclosporine to azathioprine 1 year after renal transplantation: a prospective, randomized study from 1 to 6 years after transplantation. Nephrol Dial Transplant 1993; 8: 250
18. MacPhee IAM, Bradley JA, Briggs JD, et al. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 1998; 66: 1186
19. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321
20. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029
21. Sollinger HW, for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate Mofetil for the prevention of acute rejection in cadaveric renal allograft recipients. Transplantation 1995; 60: 225
22. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients. A pooled efficacy analysis of three randomized double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39
23. Holt DW, Jones K, Lee T, Stadler P, Johnston A. Quality assessment issues of new immunosuppressive drugs and experimental experience. Ther Drug Monitor 1996; 18: 362
24. van Gelder T, Klaassen RJL, van Riemsdijk-van Overbeeke IC, IJzermans JNM, Weimar W. Mycophenolate mofetil and prednisone as maintenance treatment after kidney transplantation. Transplantation 1997; 63: 1530
25. Zanker B, Schneeberger H, Rothenpieler U, et al. Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression. Transplantation 1998; 66: 44
26. Mathew TH, for the Tricontinental Mycophenolate Mofetil Study Group. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998; 65: 1450
27. Sullivan SD, Garrison LP Jr, Best JH, et al. J Am Soc Nephrol 1997; 8: 1592.
28. van Besouw NM, van der Mast BJ, de Kuiper P, et al. Donorspecific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 2000; 70: 136.